Medical management of asymptomatic primary hyperparathyroidism: Proceedings of the Third International Workshop

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 2, 2009, Pages 373-381

  Khan, Aliya ^a   Grey, Andrew ^b   Shoback, Dolores ^c  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIMIMETIC AGENT; CALCIUM; CINACALCET; CLODRONIC ACID; ESTROGEN; ETHINYLESTRADIOL; N [3 (2 CHLOROPHENYL)PROPYL] 1 (3 METHOXYPHENYL)ETHYLAMINE; NORETHISTERONE; PAMIDRONIC ACID; PARATHYROID HORMONE; PHOSPHORUS; PLACEBO; PYROPHOSPHORIC ACID DERIVATIVE; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

BONE DENSITY; BONE DISEASE; BONE TURNOVER; CLINICAL TRIAL; CONFERENCE PAPER; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG MEGADOSE; FRACTURE; HEADACHE; HORMONE SUBSTITUTION; HUMAN; HYPOCALCEMIA; MULTIPLE CYCLE TREATMENT; NAUSEA; PARESTHESIA; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; SINGLE DRUG DOSE;

EID: 59749096226     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-1762     Document Type: Conference Paper

References (55)

1. Bilezikian JP, Potts Jr JT, El-Hajj Fuleihan G, Kleerekoper M, Neer R, Peacock M, Rastad J, Silverberg SJ, Udelsman R, Wells Jr SA 2002 Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab 87:5353-5361
2. Rubin MR, Bilezikian JP, McMahon DJ, Jacobs T, Shane E, Siris E, Udesky J, Silverberg SJ 2008 The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab 93:3462-3470
3. Sejean K, Calmus S, Durand-Zaleski I, Bonnichon P, Thomopoulos P, Cormier C, Legmann P, Richard B, Bertagna XY, Vidal-Trecan GM 2005 Surgery versus medical follow-up in patients with asymptomatic primary hyperparathyroidism: a decision analysis. Eur J Endocrinol 153:915-927
4. Zanocco K, Angelos P, Sturgeon C 2006 Cost effectiveness analysis of parathyroidectomy for asymptomatic primary hyperparathyroidism. Surgery 140:874-881
5. Zanocco K, Sturgeon C 2008 How should age at diagnosis impact treatment strategy in asymptomatic primary hyperparathyroidism? A cost-effectiveness analysis. Surgery 144:290-298
6. Rao DS, Phillips ER, Divine GW, Talpos GB 2004 Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab 89:5415-5422
7. Bollerslev J, Jansson S, Mollerup CL, Nordenstrom J, Lundgren E, Torring O, Varhaug J-E, Baranowski M, Aanderud S, Franco C, Freyschuss B, Isaksen GA, Ueland T, Rosen T 2007 Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. J Clin Endocrinol Metab 92:1687-1692
8. Ambrogini E, Cetani F, Cianferotti L, Vignali E, Banti C, Viccica G, Oppo A, Miccoli P, Berti P, Bilezikian JP, Pinchera A, Marcocci C 2007 Surgery or surveillance of mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J Clin Endocrinol Metab 92:3114-3121
9. Iskander J, Rao D 2007 Long term morbidity and mortality in untreated mild primary hyperparathyroidism. J Bone Miner Res 22:S353
10. Bolland MJ, Grey AB, Orr-Walker BJ, Horne AM, Evans MC, Clearwater JM, Gamble GD, Reid IR 2008 Prospective 10-year study of postmenopausal women with asymptomatic primary hyperparathyroidism. N Z Med J 121:18-29
11. Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP 1999 A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 341:1249-1255
12. Khan SA, Kanis JA, Vasikaran S, Kline WF, Matuszewski BK, McCloskey EV, Beneton MNC, Gertz BJ, Schiberras DG, Holland SD, Orgee J, Coombes GM, Rogers SR, Porras AG 1997 Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res 12:1700-1707
13. Meunier PJ, Arlot M, Chavassieux P, Yates AJ 1999 The effects of alendronate on bone turnover and bone quality. Int J Clin Pract Suppl 101:14-17
14. Sambrook P, Cooper C 2006 Osteoporosis. Lancet 367:2010-2018
15. Shane E, Baquiran DC, Bilezikian JP 1981 Effects of dichloromethylene diphosphonate on serum and urinary calcium in primary hyperparathyroidism. Ann Intern Med 95:23-27
16. Hamdy N, Gray RE, McCloskey E, Galloway J, Rattenbury JM, Brown CB, Kanis JA 1987 Clodronate in the medical management of hyperparathyroidism. Bone 8(Suppl 1):S69-S77
17. Adami S, Mian M, Bertoldo F, Rossini M, Jayawerra P, O'Riordan JL, Lo Cascio V 1990 Regulation of calcium parathyroid hormone feedback in primary hyperparathyroidism. Effects of bisphosphonate treatment. Clin Endocrinol (Oxf) 33:391-397
18. Licata AA, O'Hanlon E 1983 Treatment of hyperparathyroidism with etidronate disodium. JAMA 249:2063-2064
19. Schmidli RS, Wilson I, Espiner EA, Richards AM, Donald RA 1990 Aminopropylidine diphosphonate (ADP) in mild primary hyperparathyroidism: effects on clinical status. Clin Endocrinol (Oxf) 32:293-300
20. Reasner CA, Stone MD, Hosking DJ, Ballah A, Mundy GR 1993 Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate. J Clin Endocrinol Metab 77:1067-1071
21. Rossini M, Gatti D, Isaia G, Sartori L, Braga V, Asami S 2001 Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. J Bone Miner Res 16:113-119
22. Chow CC, Chan WB, Li JK, Chan NW, Chan MHM, Ko GTC, Lo KW, Cockram CS 2003 Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 88:581-587
23. Khan AA, Bilezikian JP, Kung AW, Ahmed MM, Dubois SJ, Ho AYY, Schussheim D, Rubin MR, Shaikh AM, Silverberg SJ, Standish TI, Syed Z, Syed ZA 2004 Alendronate in primary hyperparathyroidism: a double blind, randomized, placebo controlled trial. J Clin Endocrinol Metab 89:3319-3325
24. Parker CR, Blackwell PJ, Fairbairn KJ, Hosking DJ 2002 Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: a 2-year study. J Clin Endocrinol Metab 87:4482-4489
25. Marcus R, Madvig P, Crim M, Pont A, Kosek J 1984 Conjugated estrogens in the treatment of postmenopausal women with hyperparathyroidism. Ann Intern Med 100:633-640
26. Selby PL, Peacock M 1986 Ethinyl estradiol and norethindrone in the treatment of primary hyperparathyroidism in postmenopausal women. N Engl J Med 314:1481-1485
27. Grey AB, Stapleton JP, Evans MC, Tatnell MA, Reid IR 1996 Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. A randomized, controlled trial. Ann Intern Med 125:360-368
28. Orr-Walker BJ, Horne AM, Evans MC, Clearwater JM, Horne A, Grey AB, Reid IR 1999 Hormone replacement therapy causes a respiratory alkalosis in normal postmenopausal women. J Clin Endocrinol Metab 84:1997-2001
29. Aitken JM, Lindsay R, Hart DM 1974 The redistribution of body sodium in women on long-term oestrogen therapy. Clin Sci Mol Med 47:179-187
30. Lindsay R, Hart DM, Forrest C, Baird C 1980 Prevention of spinal osteoporosis in oophorectomised women. Lancet 2:1151-1154
31. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women's Health Initiative Investigators 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333
32. Orr-Walker BJ, Evans MC, Clearwater JM, Horne A, Grey AB, Reid IR 2000 Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism: four-year follow-up and comparison with healthy postmenopausal women. Arch Intern Med 160:2161-2166
33. Diamond T, Ng AT, Levy S, Magarey C, Smart R 1996 Estrogen replacement may be an alternative to parathyroid surgery for the treatment of osteoporosis in elderly postmenopausal women presenting with primary hyperparathyroidism: a preliminary report. Osteoporos Int 6:329-333
34. Guo CY, Thomas WE, al-Dehaimi AW, Assiri AM, Eastell R 1996 Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 81:3487-3491
35. Riggs BL, Hartmann LC 2003 Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice. N Engl J Med 348:618-629
36. Reid IR, Eastell R, Fogelman I, Adachi JD, Rosen A, Netelenbos C, Watts NB, Seeman E, Ciaccia AV, Draper MW 2004 A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women. Arch Intern Med 164:871-879
37. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK 2006 Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355:125-137
38. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637-645
39. Rubin MR, Lee KH, McMahon DJ, Silverberg SJ 2003 Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 88:1174-1178
40. Zanchetta JR, Bogado CE 2001 Raloxifene reverses bone loss in postmenopausal women with mild asymptomatic primary hyperparathyroidism. J Bone Miner Res 16:189-190
41. Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, Kifor O, Sun A, Hediger MA, Lytton J, Hebert SC 1993 Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 366:575-580
42. Nemeth EF, Steffey ME, Hammerland LG, Hung BC, Van Wagenen BC, Del-Mar EG, Balandrin MF 1998 Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 95:4040-4045
43. Antoniucci D, Shoback D 2002 Calcimimetics in the treatment of primary hyperparathyroidism. J Bone Miner Res 17(Suppl 2):N141-N145
44. Hofer AM, Brown EM 2003 Extracellular calcium sensing and signaling. Nat Rev Mol Cell Biol 4:530-538
45. Nemeth EF 2004 Calcimimetic and calcilytic drugs: just for parathyroid cells? Cell Calcium 35:283-289
46. Steddon SJ, Cunningham J 2005 Calcimimetic and calcilytics - fooling the calcium receptor. Lancet 365:2237-2239
47. Nemeth EF, Heaton WH, Miller M, Fox J, Balandrin MF, Van Wagenen BC, Colloton M, Karbon W, Scherrer J, Shatzen E, Rishton G, Scully S, Qi M, Harris R, Lacey D, Martin D 2004 Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther 308:627-635
48. Colloton M, Shatzen E, Miller G, Stehman-Breen C, Wada M, Lacey D, Martin D 2005 Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int 67:467-476
49. Imanishi Y, Hosokawa Y, Yoshimoto K, Schipani E, Mallya S, Papanikolaou A, Kifor O, Tokura T, Sablosky M, Ledgard F, Gronowicz G, Wang TC, Schmidt EV, Hall C, Brown EM, Bronson R, Arnold A 2001 Primary hyperparathyroidism caused by parathyroid-targeted overexpression of cyclin D1 in transgenic mice. J Clin Invest 107:1092-1102
50. Kawata T, Imanishi Y, Kobayashi K, Kenko T, Wada M, Ishimura E, Miki T, Nagan N, Inaba M, Arnold A, Nishizawa Y 2005 Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism. Eur J Endocrinol 153:587-594
51. Silverberg SJ, Bone HG, Marriott TB, Locker FG, Thys-Jacobs S, Dziem G, Kaatz S, Sanguinetti EI, Bilezikian JP 1997 Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. N Engl J Med 337:1506-1510
52. Collins MT, Skarulis MC, Bilezikian JP, Silverberg SJ, Speigel AM, Marx SJ 1998 Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J Clin Endocrinol Metab 83:1083-1088
53. Shoback DM, Bilezikian JP, Turner SA, McCary LC, Guo MD, Peacock M 2003 The calcimimetic AMG 073 normalizes serum calcium in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 88:5644-5649
54. Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D 2005 Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 90:135-141
55. Peacock M, Scumpia S, Bolognese MA, Borofsky MA, Olson K, McCary LC, Schwanauer LE, Shoback DM 2006 Long-term control of primary hyperparathyroidism with cinacalcet HCl. J Bone Miner Res 21(Suppl 1):S38